Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc.

District Court, S.D. New York·Decided August 30, 2021·No. 1:19-cv-03351·Unknown

Opinion

UNITED STATES DISTRICT COURT DATE FILED: 8/30/20 21 SOUTHERN DISTRICT OF NEW YORK ------------------------------------------------------------------- X : AQUAVIT PHARMACEUTICALS, INC., : : Plaintiff, : 19-CV-3351 (VEC) : -against- : ORDER : U-BIO MED, INC., GLOBAL MEDI PRODUCTS, : and NYUN SHI EUM aka NYON-SIK EUM, : : Defendants. : : ------------------------------------------------------------------- X VALERIE CAPRONI, United States District Judge: WHEREAS on April 15, 2019, Aquavit Pharmaceuticals, Inc. (“Plaintiff”) filed a complaint against U-Bio Med, Inc. and Nyun Shi Eum (collectively “Defendants”),1 Compl., Dkt. 1; WHEREAS both Plaintiff and Defendants claim they have the right to use the trademark AQUAGOLD, as well as other marks, in different countries in connection with a micro-injection device with medical and cosmetic applications, Aquavit Pharms., Inc. v. U-Bio Med, Inc., No. 19-CV-3351, 2020 WL 1900502, at *1 (S.D.N.Y. Apr. 17, 2020) (“Contempt Order”); WHEREAS on June 21, 2019, the Court entered a modified preliminary injunction (“MPI”) prohibiting Defendants from using AQUAGOLD and other marks in the United States, South Korea, and all other countries except for countries in which Defendants have registered their marks, MPI, Dkt. 65 at 7–11; 1 The complaint was also filed against Global Medi Products. See Compl., Dkt. 1. Global Medi Products never appeared in this action. On September 1, 2020, the Court entered a default judgment against Global Medi Products. See Default Judg., Dkt. 192. WHEREAS the MPI requires that Defendants include a disclaimer when they sell their Aquagold device in countries in which they own the marks, stating that their products are manufactured by a different company than the company that manufactures the Aquagold device that is sold in the United States and South Korea, id. at 10–11; WHEREAS the MPI prohibits Defendants from associating their products with Plaintiff’s

American or Korean trademarks or with Plaintiff’s product, id.; WHEREAS the MPI also prohibits Defendants from disparaging Plaintiff’s devices, id.; WHEREAS on April 17, 2020, the Court found Defendants in contempt for failing to comply with the MPI on numerous occasions, see Contempt Order, 2020 WL 1900502, at *1, *5–7; WHEREAS the Court awarded Plaintiff compensatory sanctions equal to 75% of Plaintiff’s attorneys’ fees and costs expended in connection with its contempt motion, id. at *10; WHEREAS on May 1, 2020, Plaintiff informed the Court that Defendants were continuing to violate the MPI, Letter, Dkt. 167;

WHEREAS on August 11, 2020, given Defendants’ ongoing violations of the MPI, the Court ordered additional compensatory sanctions, consisting of profits earned and to be earned by Defendants from sales that violate or violated the MPI, Order, Dkt. 180; WHEREAS on August 11, 2020, the Court referred the determination of the amount of compensatory sanctions to Magistrate Judge Lehrburger for the preparation of a report and recommendation (“R&R”), Orders, Dkts. 180, 181; 28 U.S.C. § 636(b); WHEREAS on August 26, 2020, Plaintiff moved for an order to show cause why coercive sanctions should not be levied against Defendants given their ongoing violations of the MPI, Motion, Dkt. 185; WHEREAS on August 26, 2020, the Court referred the motion for coercive sanctions to Judge Lehrburger to be addressed in the same R&R as the determination of the amount of compensatory sanctions, Order, Dkt. 186; WHEREAS on September 2, 2020, the Court clarified that the R&R should also address whether any delay by Defendants in complying with the MPI was justified and noted that if

Defendants finally and fully comply with the MPI, there would be no need for coercive sanctions, Endorsement, Dkt. 194 at 6; WHEREAS the parties fully briefed the various sanctions-related issues, see Dkts. 213– 218, 227–231, 232–237, 243–246, 247, 259–261, 264–267, 269; WHEREAS on July 16, 2021, Judge Lehrburger entered an R&R on the sanctions-related issues, R&R, Dkt. 272; WHEREAS in the R&R, Judge Lehrburger notified the parties that, pursuant to 28 U.S.C. § 636(b)(1) and Fed. R. Civ. P. 72(b), they had fourteen days to file written objections to the R&R’s findings, id. at 73–74;

WHEREAS Judge Lehrburger further noted that failure to file objections would result in both the waiver of objections and the preclusion of appellate review, id. at 74 (using bold font and all capital letters); WHEREAS on July 30, 2021, Plaintiff filed an objection to one of Judge Lehrburger’s findings in the R&R, Objections, Dkts. 278, 279; WHEREAS Defendants did not file any objections to the R&R; WHEREAS in reviewing an R&R, a district court “may accept, reject, or modify, in whole or in part, the findings or recommendations made by the magistrate judge,” 28 U.S.C. § 636(b)(1)(C); WHEREAS as to the portions of an R&R to which no party objects, the Court may accept those findings provided that “there is no clear error on the face of the record,” Heredia v. Doe, 473 F. Supp. 2d 462, 463 (S.D.N.Y. 2007) (quoting Nelson v. Smith, 618 F. Supp. 1186, 1189 (S.D.N.Y. 1985)); see also Fed. R. Civ. P. 72(b) advisory committee’s note; WHEREAS an error is clear when the reviewing court is left with a “definite and firm

conviction that a mistake has been committed,” see Cosme v. Henderson, 287 F.3d 152, 158 (2d Cir. 2002) (quoting McAllister v. United States, 348 U.S. 19, 20 (1954)); and WHEREAS when specific objections are made, “[t]he district judge must determine de novo any part of the magistrate judge’s disposition that has been properly objected to,” Fed. R. Civ. P. 72(b)(3); IT IS HEREBY ORDERED that the R&R is adopted in part and modified in part. The Court finds no clear error in the four findings of the R&R to which neither party objected. With respect to compensatory sanctions, Judge Lehrburger concluded that the determination of the dollar amount of profits to be disgorged as compensatory sanctions for Defendants’ violations of

the MPI should be deferred until the completion of all discovery. See R&R, Dkt. 272 at 30–55. The Court finds no clear error in Judge Lehrburger’s careful analysis or in his conclusion that Defendants’ sales data and Plaintiff’s speculative inferences “hardly provide a reliable basis for determining Defendants’ profits to be disgorged.” Id. at 35. Moreover, the Court agrees that additional information is needed with respect to the allocation of sales on a country-by-country basis and the apportionment of any non-contemptuous sales that would reduce the total. Id. at 54–55. Accordingly, the Court adopts Judge Lehrburger’s recommendation that determination of the amount of Defendants’ ill-gotten gains must await completion of all discovery so that the Court will have the benefit of the complete record.

Free access — add to your briefcase to read the full text and ask questions with AI

Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc., (S.D.N.Y. 2021).

Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc. (Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

McAllister v. United States
348 U.S. 19 (Supreme Court, 1954)
Nelson v. Smith
618 F. Supp. 1186 (S.D. New York, 1985)
Heredia v. Doe
473 F. Supp. 2d 462 (S.D. New York, 2007)